SEC Form 4 · accession 0001209191-17-053691
SANGAMO THERAPEUTICS, INC · SGMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William R Ringo
Director
Period of report
Sep 20, 2017
Accepted (ET)
Sep 22, 2017 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001233
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 20, 2017 | M | 31,000 | $6.05 | A | 31,800 | D | |
| Common StockF1 | Sep 20, 2017 | S | 31,000 | $14.3741 | D | 800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $6.05 | Sep 20, 2017 | M | 31,000 | D | — | Apr 15, 2020 | Common Stock | 31,000 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F2The shares underlying the stock option are fully vested and exercisable.